- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05832099
Cognition-preserving Brain Irradiation for Treating Patients With Intracranial Meningioma in the Era of Modern Radiotherapeutic Techniques Including Proton Beam Therapy - a Prospective Study Focusing on Radiological Outcomes and Neurocognitive Endpoints
【Background】For cranial-irradiation-naive patients with intracranial meningiomas at risk of local recurrence, the administration of conformal cranial radiotherapy can enhance tumor control in the current era of modern radiotherapeutic techniques. Life expectancy in patients with intracranial meningiomas, particularly non-malignant meningiomas (WHO grade I and II) is essentially similar to people of general population. However, RT-related neurocognitive function (NCF) sequelae are potentially and seriously a concern which should not be ignored. In terms of the natural course of cranial irradiation-induced NCF decline, it might vary considerably according to the specific domains which are selected to be measured. Early neurocognitive decline principally involves impairments of episodic memory, which is significantly associated with functions of the hippocampus. Additionally, the extent of changes in hippocampal volume after local irradiation may be associated with the hippocampal dosimetry. This study thus aims to investigate the potential cause-effect relationship between the hippocampal dosimetry and radiological outcomes represented by the volumetric changes regarding the contralateral hippocampus; furthermore, the correlation between radiological outcomes and neurocognitive endpoints will be examined and clarified.
【Methods】Patients with cranial-RT-naive intracranial meningiomas may be eligible and therefore enrolled in this prospective study addressing both radiological outcomes and neurocognitive endpoints. All eligible and recruited patients should receive baseline volumetric brain MRI examination and baseline neurobehavioral assessment. Subsequently, conformal cranial irradiation in the era of modern radiotherapeutic techniques (including hypofractionated stereotactic radiotherapy, proton beam therapy volumetric modulated arc therapy) will be utilized in order to reduce the dose irradiating the contralateral hippocampus and other relevant organs at risk. The prescribed dose schemes for treating patients with intracranial meningioma depend on the decision of the radiation oncologist in charge and follow the treatment guidelines at our cancer center. Accordingly, a battery of neurocognitive measures, which includes 9 standardized neuropsychological tests categorized into 5 NCF domains (e.g., executive functions, verbal & non-verbal memory, working memory, psychomotor speed, and amygdala-related emotion recognition), is used to evaluate neurocognitive performances longitudinally for our registered patients. There will be two co-primary outcome measures in the current study. The main primary outcome will be the correlation between the mean hippocampal dose and the extent of change in hippocampal volume at 6 months after the course of cranial RT. The other primary endpoint will be 6-month cognitive-deterioration-free survival.
【Expected Results】This prospective observational cohort study aims to explore and investigate the cause-effect relationship between the hippocampal dosimetry (i.e., mean dose irradiating the hippocampus, particularly the one contralateral to the lateralization of intracranial meningioma) and the extent of hippocampal atrophy signifying one of the measures regarding radiological outcomes. Simultaneously, predefined standardized neurocognitive outcome measures such as hippocampus-related memory functions and amygdala-related emotion recognition will be obtained prospectively and longitudinally in order to examine whether any meaningfully significant correlation exists between the above radiological outcome measures and neurocognitive endpoints. The mutual associations among hippocampal dosimetry, radiological outcomes including the MRI-delineated hippocampal volume, and neurocognitive endpoints including hippocampus-related verbal/non-verbal memory functions will be examined thoroughly.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Chi-Cheng Chuang, M.D.
- Phone Number: 2412 +88633281200
- Email: ccc2915@cgmh.org.tw
Study Contact Backup
- Name: Shinn-Yn Lin, M.D.
- Phone Number: 7172 +88633281200
- Email: rt3126@cgmh.org.tw
Study Locations
-
-
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with clinically or pathologically-confirmed intracranial non-malignant meningiomas who are at least 18 years old, referred for arranging conformal radiotherapy
- A Fair/good performance status superior to Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70
Exclusion Criteria:
- History of prior radiotherapy delivered to brain/head region for any reason, including stereotactic radiosurgery
- Patients with malignant meningiomas diagnosed pathologically (WHO grade III)
- Patients with presumed clinical target volume (CTV) encompassing bilateral peri-hippocampal regions within 5 mm away from the adjacent periphery of the hippocampus
- Patients whose quality of volumetric MRI fails to meet the minimal requirements for physicians to delineate the hippocampal contouring (i.e., slice thickness > 2mm)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Radiation
Conformal focal-brain irradiation using modern radiotherapeutic techniques (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
|
The techniques of conformal focal-brain irradiation in the era of modern radiotherapy (i.e., conventionally fractionated VMAT, hypofractionated stereotactic radiotherapy, and proton beam therapy, etc)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Longitudinal changes in the volumes of organs at risk including the hippocampus
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Longitudinal changes in the volumes (cc) of the left hippocampus, right hippocampus, left amygdala, right amygdala, left thalamus, right thalamus, and so on based on volumetric MR imaging examinations
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in verbal memory function
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in verbal memory function related to left hippocampus from baseline to 4 months after cognition-preserving cranial RT
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in non-verbal memory learning
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in non-verbal memory learning associated with right hippocampus from baseline to 4 months after cognition-preserving brain RT
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in executive function
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in executive function related to hippocampus from baseline to 4 months after cognition-preserving cranial RT. Concerning the domain of executive functions generally dominated by the frontal lobes, the Modified Card Sorting Test is employed to assess both conceptual formation and mental shifting which have been documented to be the major components of executive functions. |
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in emotion memory task
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in emotion memory tasks associated with the amygdala from baseline to 4 months after cognition-reserving cranial irradiation. For evaluate and quantify the cognitive function of amygdala, the NCF test tailored to the emotional recognition task will be used and patients' performances will be assessed using the commercialized and computerized test included in Cambridge Cognition® package. |
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in working memory
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Change in working memory related to hippocampus from baseline to 4 months after cognition-preserving cranial RT. Working memory includes executive functions and psychomotor speed.
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Longitudinal changes in the imaging biomarkers
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Longitudinal changes in the imaging biomarkers from DTI imaging
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Longitudinal changes in the fractional anisotropy
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Longitudinal changes in the fractional anisotropy (FA, unitless index between 0 and 1) from DTI imaging
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Trajectories in the imaging biomarker
Time Frame: baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Trajectories in the imaging biomarker, mean diffusivity (MD, mm squared/second) based on DTI imaging
|
baseline (pre-RT), 4 months, 8-10 months (optional), 12 months, 18 months, 24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202202092A3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Meningioma
-
NRG OncologyNational Cancer Institute (NCI)RecruitingIntracranial Meningioma | Grade II MeningiomaCanada, United States, Japan, Saudi Arabia, India
-
SCRI Development Innovations, LLCNovartis; Genentech, Inc.TerminatedIntracranial MeningiomaUnited States
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Active, not recruiting
-
Assaf-Harofeh Medical CenterUnknownIntracranial Meningioma | Neurologic DeficitsIsrael
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...RecruitingIntracranial Meningioma | Recurrent Meningioma | NF2 Gene MutationUnited States
-
University Hospital, MontpellierCentre Hospitalier Universitaire de BesanconRecruitingAtypical Meningioma | Anaplastic Meningioma | Clear-cell Meningioma | Chordoid Meningioma | Rhabdoid Meningioma | Papillary MeningiomaFrance
-
Northwestern UniversityNational Cancer Institute (NCI); NovoCure Ltd.RecruitingAtypical Meningioma | Grade III Meningioma | Recurrent Meningioma | Anaplastic (Malignant) Meningioma | Grade II Meningioma | Supratentorial MeningiomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGrade 1 Meningioma | Grade 2 Meningioma | Grade 3 Meningioma | Recurrent Meningioma | Unresectable MeningiomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingSchwannoma | Grade III Meningioma | Intracranial Neoplasm | Nerve Sheath Neoplasm | Grade II Meningioma | Grade I Meningioma | Pituitary Gland AdenomaUnited States
-
Nancy Ann Oberheim Bush, MDMerck Sharp & Dohme LLCRecruitingRecurrent Meningioma | Grade I Meningioma, Adult | Grade II Meningioma, Adult | Grade III Meningioma, AdultUnited States
Clinical Trials on Radiation
-
Canadian Cancer Trials GroupAlliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaboratorsRecruitingBreast CancerUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Terminated
-
Massachusetts General HospitalCompletedMesenchymal TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
University of Texas Southwestern Medical CenterCompletedNon-small Cell Lung CancerUnited States
-
Maastricht Radiation OncologyThe Netherlands Cancer Institute; Diakonessenhuis, UtrechtCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States